Misoone (Misoprostol)

Misoprostol mimics prostaglandin E1 and binds to EP2 and EP3 receptors in the gastrointestinal tract and uterus. In the stomach, receptor activation raises cyclic AMP, which increases mucus and bicarbonate secretion, strengthening the protective barrier. In the uterus, the same signaling pathway triggers smooth‑muscle contraction, facilitating labor or abortion processes.

The specific dose of Misoone is determined by the prescribing clinician based on the indication, patient characteristics, and local guidelines. Dosage may differ for ulcer prevention, obstetric use, or hemorrhage control, and the prescriber will provide exact instructions on strength, frequency, and duration.

Misoone is classified as pregnancy category X because it can cause uterine contractions and fetal harm. It is contraindicated in pregnant women except when used for medically supervised termination of pregnancy. Safety during breastfeeding has not been established, and the drug is generally avoided in lactating patients.

To request Misoone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The primary alternative to misoprostol for gastric protection is a combination of a proton‑pump inhibitor with an H2‑receptor antagonist, while dinoprostone (prostaglandin E2) is another uterine‑active prostaglandin. Misoprostol offers a broader range of indications, is available in oral form, and has a well‑characterized safety profile, whereas alternatives may differ in route, potency, and side‑effect spectrum.

Misoone should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in areas with high humidity or direct sunlight to maintain its stability.

Misoone is administered orally, usually as a tablet or capsule taken with water. The exact method—such as taking it with food or on an empty stomach—depends on the indication and the prescriber’s instructions. Patients should follow the dosing schedule provided by their healthcare professional.

Serious risks include severe uterine bleeding, especially during obstetric use, and allergic reactions that can progress to anaphylaxis. Persistent vomiting and dehydration are also concerning. Patients should seek immediate medical attention if they experience heavy vaginal bleeding, difficulty breathing, swelling of the face or throat, or inability to keep fluids down.

Misoone is contraindicated in pregnant women (except for supervised termination), patients with known hypersensitivity to misoprostol or other prostaglandin analogues, and individuals with severe renal impairment where dose adjustment is not feasible. Caution is also advised for patients with active gastrointestinal bleeding or severe cardiovascular disease.